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3/$178-Hydroxysteroid ehydrogenase (3/?17bHSDH) is an NAD-dependent dehydrogenase which has a 
double specificity for the 3- and 17-positions on the steroid skeleton. When dehydroepiandrosterone 
(DHEA) is used as steroid substrate, and the assay coupled with ketosteroid-isomerase, the two reactions 
occur alternately and each reaction on the 3-position produces a chromophoric molecule. These two reac- 
tions can follow one another without dissociation of the coenzyme from the enzyme binding site. This is 
confirmed by competition experiments with another dehydrogenase. 
3817/3-Hydroxysteroid dehydrogenase A5-3-Ketosteroid isomerase Bifunctional enzyme 
Dehydroepiandrosterone Pseudomonas testosteroni NAD regeneration 
1. INTRODUCTION 
3,&,17,&Hydroxysteroid ehydrogenase (3P17P 
HSDH, EC 1.1.1.5 1) is an inducible enzyme pro- 
duced by Pseudomonas testosteroni. This enzyme 
catalyses the reversible oxidation of both 3- and 
17-hydroxy groups of some hydroxysteroids. Since 
the original report [l], it has been confirmed by 
several authors that the 3 and 17 activities are 
associated with the same protein [2,3]. 
It is not known, however, if 3 and 17 de- 
hydrogenations occur at the same active site, 
whether they share a common catalytic site but 
have different steroid binding regions or if 
separate active sites are present [4]. This report 
deals with this open question. 
When dehydroepiandrosterone (DHEA) is used 
* To whom correspondence should be addressed 
Abbreviations: isomerase, A5-3-ketosteroid isomerase; 
DHEA, dehydroepiandrosterone (3-hydroxy-17-oxo- 
androst-5-ene); YADH, yeast alcohol dehydrogenase 
as steroid substrate, the enzyme is able to catalyse 
both reduction of the 17-0~0 group and oxidation 
of the 3-hydroxy group. In this way, the cyclic 
transformation of coenzyme in catalytic quantity 
was applied to an interesting analytical method of 
NAD amplification [5]. 
We show here that in such a reaction pathway, 
the reaction in the 17-position can be followed by 
the reaction in the 3-position without dissociation 
of the coenzyme from the enzyme binding site. 
2. MATERIALS AND METHODS 
3fl17PHSDH and ketosteroid isomerase were 
gifts from SEMPA-Chimie (Palaiseau, France). 
Purification procedures are described in [6,7] for 
the two enzymes. 3fi17,&HSDH purchased from 
Sigma was also used with the same results. 
3P17PHSDH activity was measured by the rate of 
NADH formation monitored at 340 nm. The assay 
mixture contained 1.5 pmol NAD+, 0.3 $mol 
testosterone, 0.3 mmol sodium pyrophosphate 
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(pH 9.5), 0.1 ml methanol in a total volume of 
3 ml. The reaction was initiated by addition of en- 
zyme. One unit is defined as the formation of 
1 pmol NADH/min. 
The velocity of the reaction catalysed by 
3,817PHSDH coupled with isomerase was 
measured by the rate of A4-androstenedione (and 
testosterone) production monitored at 248 nm 
(cm = 17000 M-’ .cm-I). The assay mixture con- 
tained 0.6pmol DHEA, 0.15 mmol sodium 
phospohate (pH 7.4), 0.3 ml methanol, in a total 
volume of 3 ml. The reaction was initiated by addi- 
tion of both isomerase (5 units) and 3@17/3HSDH 
(0.125 units). In competition experiments by the 
YADH reaction, the velocity of the cyclic reaction 
was measured in the presence of YADH with 
ethanol as substrate (30~1). In control ex- 
periments, we did not observe inhibition or activa- 
tion due to YADH or ethanol added separately. 
3. RESULTS 
3.1. Reaction path way 
The reaction pathway of the 3,&17flHSDH- 
isomerase reaction with DHEA as substrate is 
shown in fig.1. The irreversible isomerisation of 
A5-androstenedione to A4-androstenedione acts as 
a driving force and produces a chromophoric 
molecule. A5Androstenedione is in a very low 
steady-state concentration since isomerase activity 
is in large excess. 
As described in fS,8], further reactions on the 
two precedent products can occur giving rise to 
testosterone: 
A4-androstenedione 17 activity 
DHEA- 
*testosterone (em = 17~ M-‘*cm-‘) 
\ 
NADH-lNAD’,,fsomerisation 
androstenediol 
3 activity ,/*’ 
NAD+QNADH 
HSDW17activity) 
Androstenediol 
A 5 Androstenedione A4 Androstenedione 
&MCk 248nm)=l7~ M 
-1 -I 
cm 
Fig.1. Reaction pathway of the 3,d17,dHSDH-isomerase reaction with DHEA as substrate. 
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In these experimental conditions, only 10% of the 
absorbance variation is due to testosterone pro- 
duced by these further reactions. 
Simplifying the following discussion, only the 
first two reactions giving rise to androstenediol 
and A6androstenedione (fig. 1) will be considered. 
For our purpose, the secondary reactions in the 3- 
and 17-positions which produce testosterone are 
equivalent to the first ones. 
A new chromophoric molecule results from ox- 
idation of the 3&hydroxy group on androstenediol 
followed by isomerisation. Conversely the reduc- 
tion of the 17-0~0 group of A6androstenedione 
does not produce a new one. 
3.2. Reaction with coenzyme in catalytic 
concentration 
The characteristic features of the kinetic records 
performed with catalytic concentrations of coen- 
zyme are shown in fig.2. In the first step, the initial 
form of the coenzyme is consumed, and the initial 
reaction rate (VO) is then lower when the reaction 
starts with NAD+ in place of NADH. When a 
‘coenzymic steady state’ is reached, the reaction 
rates (VJ are the same whatever the initial form of 
the coenzyme: reduced or oxidized. The difference 
between these two steps (V,, V,) becomes pro- 
gressively less distinct as coenzyme concentration 
increases. When the initial NAD+ or NADH con- 
Fig.2. Kinetic records with low coenzyme 
concentrations. (-) Absorbance (h = 248 nm), 
(---) fluorescence (h,, = 340 nm, A,,,, = 455 nm). As 
indicated by arrows reaction starts with NAD+ = 1 pM 
or NADH = 1 FM. V, is the reaction velocity measured 
when the coenzymic steady state is reached. 
Table 1 
Maximal activities of the 3@7,L?HSDH-isomerase 
reaction 
Symbols Initial d[Andro- d[NADH] 
coenzyme stenedione] dt 
concentrations dt (umol/min) 
(umol/min) 
V smax NAD+ or NADH 
> 1OpM 0.22 - 
v3 NAD+, 1 mM - + 0.22 
VI7 NADH, 0.1 mM - - 0.0215 
Values are for one unit of 3,617flHSDH 
centration is about 6 FM, the reaction rate remains 
constant and identical with the two forms of the 
coenzyme. From this point, the reaction rate has 
its maximum value. The increase of the initial 
NAD+ (or NADH) concentration above 6 ,uM does 
not involve an increase in reaction rate. 
3.3. Reaction with coenzyme in stoichiometric 
concentration 
When NAD is in a high initial concentration 
(millimolar range), the formation or consumption 
of NADH can be monitored at 340 nm. The values 
of these activities measured at saturating coenzyme 
concentrations are reported in table 1 (the concen- 
trations required for half maximal velocities are 
approx. 80 PM for NAD+ and 10 ,uM for NADH). 
3.4. Competition by YADH reaction 
The 3pl7flHSDH-isomerase reaction was also 
performed in the presence of YADH and ethanol. 
There is competition between the reaction cata- 
lyzed by YADH and the 17 activity of 
Fig.3. Competition for NAD+ consumption by the 
YADH reaction. 
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Fig.4. Activity vs NAD+ concentration. (0) 
3@7flHSDH-isomerase; the curve is calculated with 
V,,, = 1, K,,, = 1.2pM. (w) 3fll7PHSDH-isomerase + 
YADH (10 pg/ml) and ethanol; the curve is calculated 
with k’,,, = 0.97, K, = 0.36 AM. (Inset) Effect of YADH 
concentration, [NAD’] = 1.2 pM. 
3pl7flHSDH for the consumption of NAD’ 
(fig.3). The reaction rate has been measured in the 
presence of YADH and ethanol at various NAD+ 
concentrations (fig.4). The 3,&17PHSDH- 
isomerase reaction is not inhibited but activated by 
the YADH reaction, and only at low NAD+ con- 
centrations. This implies a decrease of the ap- 
parent K,,,. The maximal activity is not modified. 
The concentration of YADH was chosen to give a 
maximal effect as shown in the control experiment 
(fig.4, inset). 
4. DISCUSSION 
Examination of the foregoing results reveals that 
the hypothesis of two separate catalytic sites is not 
satisfactory. When the reaction starts with NADH, 
the NAD+ concentration is initially negligible. 
Thus only the 17 activity should be initially ob- 
served without formation of androstenedione. In 
fact, during the early step of the reaction course, 
the reaction rate (VO, fig.2) is not negligible and 
even higher with NADH than with NAD+. 
At high initial NADH concentration (table l), 
the A6androstenedione production rate (I’,,,,) is 
IO-fold higher than the NADH consumption 
velocity (VI,). The main fraction of the NADH 
consumed by the 17 activity is regenerated espite 
a high NADH/NAD+ ratio. This suggests that the 
NAD+ molecules produced by the 17 reaction can 
react in the 3 reaction, without dissociation from 
a single binding site. This is not true for the reverse 
reaction: when the reaction starts with a high in- 
itial NAD+ concentration, the NADH production 
is stoichiometric with the ACandrostenedione 
production (P’j = Vsmax). In this case, all the 
NADH molecules produced by the 3 reaction are 
released in the reaction medium. The existence of 
a common site for the two activities is clearly con- 
firmed by the inefficiency of the competition of an 
additional NAD+ consuming reaction. 
In the presence of the competing reaction, with 
high YADH/3/317PHSDH ratio, most of the 
NAD+ molecules released from the 3,&17,6HSDH 
binding site are shunted from the 3 reaction to the 
YADH reaction. If NAD+ does dissociate from a 
17 specific site and reassociate with a 3-specific 
site, the YADH reaction should cause a complete 
depletion of the velocity of androstenedione pro- 
duction. The activation effect which is actually 
observed reflects a shift in the coenzymic steady 
state. The activity is measured in the linear phase 
of the reaction course ( Vs, fig. l), when NAD is on- 
ly 20% in its reduced form. In the presence of the 
reaction catalyzed by YADH, this steady state is 
shifted toward a completely reduced state for 
NAD. This appears as an apparent enhanced af- 
finity because, like other NAD-dependent 
dehydrogenases, 3fll7PHSDH has a higher affinity 
for the reduced form of the coenzyme [4]. The 
symmetrical effect was also observed (not shown): 
in the presence of an additional NADH-consuming 
reaction (LDH + pyruvate) the apparent Km for 
NAD is then increased to 5.8 PM, without signifi- 
cant alteration of V,,,X. The published data on 
3fil7flHSDH were interpreted by their authors in 
various ways. Detailed considerations of the 
binding of various steroids have led to the conclu- 
sion that two different active sites, with a high 
degree of specificity are present on the enzyme sur- 
face [ 11. The opposite interpretation was also pro- 
posed [9, lo]: studies on a group of 17,& 
hydroxysteroids argue in favor of a large steroid 
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binding site. The two activities could result from 
two different fitting possibilities for the steroid. 
Inhibition by substrate excess, classically observed 
with most of the substrates, is then interpreted by 
the formation of the dead-end ternary complex 
which results from one of the two binding 
possibilities. The results reported above 
demonstrate that the two activities proceed with 
the same coenzyme binding site. This eliminates 
the possibility of two distinct catalytic sites. 
Other published results are consistent with this 
view. Binding studies indicate that there is 
statistically one NAD binding site per subunit 
(3/?17PHSDH is tetrameric), these sites being 
equivalent and independent [4]. The inhibition by 
a synthetic cyano-ketosteroid of both 3,& and 17@ 
activities has been reported [l l] indicating a struc- 
tural homology between the regions involved in 
each reaction. 
Unsuccessful attempts at affinity labelling by 
substrate and coenzyme analogs have been 
reported [4,5]. However, as far as we know, no 
more direct evidence that could be obtained by 
these methods has been published to demonstrate 
the common origin of the two activities. 
The idea that one enzyme active site may 
catalyse different stereospecific reactions is not 
completely surprising, especially for a steroid 
dehydrogenase. It was clearly demonstrated that 
the two activities of 3~,20&HSDH (EC 1.1.1 S3) 
from Sireptomyces hydrogenans and of 17p- 
oestradiol dehydrogenase-20LuHSDH are relevant 
for a single catalytic site [ 12,131. The 4 
dehydrogenases, whose 3-dimensional structures 
have been determined 1141, have subunits made of 
2 domains, one of which is similar in all 4. This do- 
main binds the NAD, the other binding the 
substrate. Our results suggest hat a single NAD 
binding domain is implicated in the 2 specificities. 
It seems likely that the two specificities also involve 
a single steroid binding domain, with possibly a 
broad steroid binding site as has been suggested 
[9]. The existence of two steroid binding domains, 
each able to interact with a single NAD binding do- 
main does not seem consistent with the known 
structural features of other dehydrogenases. The 
3~17~HSDH-isomerase reaction used in here is 
quite similar to the reaction catalysed by horse 
liver alcohol dehydrogenase (HLADH) when two 
substrates are consumed in a cyclic reaction [15]: 
S 1 (hydroxyl)-------------------------+ P 1 (carbonyl) 
,’ 
,---. 
NAD+ N;DH 
). / 
.-._“d , 
P2 (hy&oxyl)+----------------------- S2 (carbonyl) 
In our case the two substrates are located on the 
same molecule: DHEA. These spontaneous NAD- 
regenerating reactions are essential for the 
development of studies dealing with artificial and 
catalytically competent NAD-dehydrogenase com- 
plexes. The grafting of a functional NAD molecule 
at a molecular distance from the active site of 
HLADH has been described [16,17]. A prereq- 
uisite for such studies is a method that allows the 
alternative transformation of bound NAD 
molecules. Since the two activities have the same 
site on 3~17~HSDH, the reaction described in this 
work appears to be a convenient model for this 
purpose. 
4. CONCLUSION 
Despite numerous and precise data published on 
3,&17@HSDH, the fundamental question concern- 
ing the origin of the double specificity on a single 
site or on 2 different ones has not received clear 
answers. The kinetic results reported here 
demonstrate, in a simple way, the existence of a 
single catalytic site. 
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